Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2024
Business Overview: The Company operates a telemedicine platform focusing on men's wellness, specifically erectile dysfunction (Mango ED), hair loss (Mango GROW), and testosterone replacement therapy (PRIME). Products are compounded and sold online. The Company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 |
|---|---|---|
| Revenues | $377,258 | $241,959 |
| Cost of Revenues | $160,068 | $97,630 |
| Gross Profit | $217,190 | $144,329 |
| Operating Expenses | $4,753,448 | $4,995,712 |
| Net Loss | $(4,758,936) | $(4,844,910) |
| Cash and Cash Equivalents (End of Period) | $490,243 | $2,947,495 |
| Working Capital Deficit | $(860,704) | Not Reported |
| Accumulated Deficit | $(15,986,733) | $(11,228,173) |
Note: Cost of Revenues includes $109,608 in related party costs for the six months ended June 30, 2024.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased by 55.9% ($135,299) compared to the prior six-month period, driven by increased digital marketing and recurring subscriptions.
- Operating Expenses: Total operating expenses decreased by approximately 4.8% ($242,264) year-over-year. This was primarily due to a significant reduction in investor relations expenses ($336,465 decrease) and placement agent fees ($387,400 decrease), partially offset by increases in stock-based compensation ($98,303 increase) and advertising/marketing ($168,630 increase).
- Asset Acquisition: The Company acquired patents and patent applications related to infection prevention for a total consideration of $20,000,000. This was funded by issuing 980,000 shares of Series C Convertible Preferred Stock (valued at $19,600,000) and a cash payment of $400,000. This resulted in a significant increase in non-current assets.
- Financing Activity: The Company raised $1,500,000 through the sale of Series B Convertible Preferred Stock and $568,270 from the sale of common stock (including ELOC proceeds). Net cash used in operating activities was $2,568,367.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The Company has incurred recurring net losses and has an accumulated deficit of nearly $16 million. Management states that current capital resources are not sufficient to fund operations for the next 12 months. Additional funding is required, which may result in significant dilution.
- Capital Raising: The Company has entered into a Securities Purchase Agreement (SPA) and an Equity Purchase Agreement (ELOC) with an institutional investor to raise up to $25,000,000. As of the filing date, $2,500,000 in Series B Preferred Stock and warrants have been sold, and $457,655 in common stock has been sold under the ELOC.
- Related Party Transactions: Significant costs are incurred with related parties, including Epiq Scripts (pharmacy services) and loans from entities controlled by the CEO (Jacob D. Cohen). Related party cost of revenues was $109,608 for the six months ended June 30, 2024.
- Risk Factors: Key risks include the need for additional funding, potential dilution from preferred stock conversion and warrant exercises, regulatory risks regarding compounded drugs (FDA Section 503A exemption), and dependency on third-party prescribers and pharmacies.
- Unusual Items: The Company recorded a loss on the sale of assets of $18,387 related to the disposal of equipment to a related party. Additionally, $222,678 in interest expense was recorded due to the amortization of the discount on Series B Preferred Stock.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $490,243 cash balance against the stated need for additional funding to survive the next 12 months.
- Dilution Impact: Assess the potential dilution from the conversion of Series B and Series C Preferred Stock and the exercise of outstanding warrants (6,185,000 warrants outstanding).
- Related Party Terms: Review the Master Services Agreement with Epiq Scripts to ensure terms are at arm's length, given the CEO's ownership interest.
- Patent Valuation: Evaluate the strategic value and potential revenue generation of the $20 million patent acquisition relative to the Company's current cash burn.
- Regulatory Compliance: Confirm the status of the FDA Section 503A exemption for compounded products and any ongoing regulatory inquiries.